28mon MSN
Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.
Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable.
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...
But at this point, Eli Lilly is stacking wins, and Novo is running out of room to surprise. Investors will be watching the next data drop closelybecause in the high-stakes obesity drug market ...
One of the world’s largest studies of Ozempic, Mounjaro and other blockbuster diabetes and obesity drugs highlighted their ...
Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...
Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback